The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Open accessAbstract
BACKGROUND: In Fabry disease, progressive glycolipid accumulation leads to organ damage and early demise, but the incidence of renal, cardiac and cerebrovascular events has not been well characterized. METHODS: We conducted a retrospective chart review of 279 affected males and 168 females from 27 sites (USA, Canada, Europe). The pre-defined study endpoints included progression of renal, cardiac and cerebrovascular involvement and/or death before the initiation of enzyme replacement therapy. RESULTS: The mean rate of estimated glomerular filtration rate (eGFR) decline for patients was -2.93 for males, and -1.02 ml/min/1.73 m(2)/year for females. Prevalence and severity of proteinuria, baseline eGFR <60 ml/min/1.73 m(2) and hypertension were associated with more rapid loss of eGFR. Advanced Fabry nephropathy was more prevalent and occurred earlier among males than females. Cardiac events (mainly arrhythmias), strokes and transient ischaemic attacks occurred in 49, 11, 6% of males, and in 35, 8, 4% of females, respectively. The mean age at death for 20 male patients was 49.9 years. CONCLUSIONS: Baseline proteinuria, reduced baseline eGFR, hypertension and male gender were associated with more rapid progression of Fabry nephropathy. The eGFR progression rate may increase with advancing nephropathy, and may differ between subgroups of patients with Fabry disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 3×
“73 m2 were classified as having CKD [15].”
BackgroundMethodInfluentialSafety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Self-citationPeterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Self-citationFabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Ries, M., & Beck, M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01309.x · Cited by 848
Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., & Wilcox, W. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00014 · Cited by 766
Self-citationMacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Self-citationFemales with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
Self-citationSAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
The Modification of Diet in Renal Disease Study
Klahr, S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903303201310 · Cited by 454
Germain, D. P., Waldek, S., Banikazemi, M., Bushinsky, D. A., Charrow, J., Desnick, R. J., Lee, P., Loew, T., Vedder, A. C., Abichandani, R., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080816 · Cited by 438
Self-citationFabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., Bultas, J., Lee, P., Sims, K., Brodie, S. E., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000237866.70357.c6 · Cited by 411
Self-citationThurberg, B. L., Rennke, H., Colvin, R. B., Dikman, S., Gordon, R. E., Collins, A. B., Desnick, R. J., & O'Callaghan, M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00675.x · Cited by 334
Self-citationWang, R. Y., Lelis, A., Mirocha, J., & Wilcox, W. R. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31802d8321 · Cited by 305
Self-citationNatural history of Fabry disease in females in the Fabry Outcome Survey
Deegan, P. B., Baehner, A. F., Barba Romero, M.-Á., Hughes, D. A., Kampmann, C., & Beck, M. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036327 · Cited by 304
Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T., & Brady, R. O. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi152 · Cited by 269
Self-citationOrtiz, A., Oliveira, J. P., Waldek, S., Warnock, D. G., Cianciaruso, B., Wanner, C., & on behalf of the Fabry Registry (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm848 · Cited by 221
Self-citationRenal Biopsy Findings in Children and Adolescents With Fabry Disease and Minimal Albuminuria
Tøndel, C., Bostad, L. H., Hirth, A., & Svarstad, E. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.12.032 · Cited by 212
Patients with Fabry disease on dialysis in the United States
Thadhani, R., Wolf, M., West, M. L., Tonelli, M., Ruthazer, R., Pastores, G. M., & Obrador, G. T. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00097.x · Cited by 200
CNS manifestations of Fabry's disease
Fellgiebel, A., Müller, M. J., & Ginsberg, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70548-8 · Cited by 186
Early renal changes in hemizygous and heterozygous patients with Fabry's disease
Gübler, M.-C., Lenoir, G., Grünfeld, J., Ulmann, A., Droz, D., Habib, R., Naizot, C., Adafer, E., & Grandhomme, C. (1978) · Kidney International · doi:10.1038/ki.1978.32 · Cited by 182
Shabbeer, J., Yasuda, M., Benson, S. D., & Desnick, R. J. (2006) · Human Genomics · doi:10.1186/1479-7364-2-5-297 · Cited by 144
Self-citationTahir, H., Jackson, L. L., & Warnock, D. G. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121400 · Cited by 131
Self-citationRule, A. D. (2007) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328057de8b · Cited by 54
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Self-citationX‐chromosome inactivation in female patients with Fabry disease
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A. A., Eladari, D., Jabbour, F., Beldjord, C., De Mazancourt, P., & Germain, D. P. (2016) · Clinical Genetics · doi:10.1111/cge.12613 · Cited by 424
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
Arends, M., Wanner, C., Hughes, D., Mehta, A., Oder, D., Watkinson, O. T., Elliott, P. M., Linthorst, G. E., Wijburg, F. A., Biegstraaten, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090964 · Cited by 416
Self-citationHughes, D. A., Nicholls, K., Shankar, S. P., Sunder-Plassmann, G., Koeller, D., Nedd, K., Vockley, G., Hamazaki, T., Lachmann, R., Ohashi, T., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104178 · Cited by 386
Self-citation
Metadata
- Authors
- Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., & Desnick, R. J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-13
- Volume
- 24
- Issue
- 7
- Pages
- 2102-2111
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2126269101
- Cited by
- 368
- References
- 31
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.